<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134580">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02032979</url>
  </required_header>
  <id_info>
    <org_study_id>13-AOI-06</org_study_id>
    <nct_id>NCT02032979</nct_id>
  </id_info>
  <brief_title>Neurological and Psychiatric Comorbidities Patients With FSHD 1 and 2</brief_title>
  <official_title>Neurological and Psychiatric Comorbidities Patients With FSHD 1 and 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to conduct a comparative pilot cognitive and psychiatric profiles
      of 10 patients Facio-Scapulo-Humeral Dystrophy (= FHSD) type 1 and 10 patients with type 2
      FSHD study. For this, the investigators relied on observational components: FSHD2 patients
      appear more often present with psychiatric comorbidities and seem to have lower cognitive
      performance compared to FSHD1 patients. This was confirmed by a preliminary study on a small
      sample population of patients. It seems to exist mainly executive dysfunction associated
      with attention disorders in patients FSHD2. Moreover, their performance in IQ tests would be
      low in relation to their socio-educational and compared with patients FSHD1 level.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Montgomery and Asberg Depression Rating Scale</measure>
    <time_frame>One time at the inclusion</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Hamilton Depression Rating Scale</measure>
    <time_frame>One time at the inclusion</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Hamilton Anxiety Rating Scale</measure>
    <time_frame>One time at the inclusion</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Quick inventory of depressive symptomatology Self report</measure>
    <time_frame>One time at the inclusion</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form</measure>
    <time_frame>One time at the inclusion</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Mini Mental Status Evaluation</measure>
    <time_frame>One time at the inclusion</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Wechsler Adult Intelligence Scale</measure>
    <time_frame>One time at the inclusion</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Muscular Dystrophy, Facioscapulohumeral</condition>
  <arm_group>
    <arm_group_label>FSHD patient</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Psychiatric test</intervention_name>
    <arm_group_label>FSHD patient</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age ≥ 18 years and &lt;75 years

          -  FSHD patients 1 or 2 with genetic confirmation

        Exclusion Criteria:

          -  Phosphokinase creatine level &gt; 5 time of the normal

          -  Patient as medical history :

               -  A history or active neurological disease likely to interfere with the
                  interpretation of results

               -  a history of head trauma

               -  an infectious disease, hormonal, inflammatory or some deficiency may induce
                  cognitive and / or psychiatric troubles

               -  Patient with cons-indication for performing a brain MRI

          -  Pregnant, parturient and lactating (producing a serum pregnancy test)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Muriel LAFFON, Dr</last_name>
    <phone>04 92 03 82 69</phone>
    <phone_ext>+33</phone_ext>
    <email>laffon.m@chu-nice.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Pasteur</name>
      <address>
        <city>Nice</city>
        <zip>06002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Muriel LAFFON, Dr</last_name>
      <phone>04 92 03 82 69</phone>
      <phone_ext>+33</phone_ext>
      <email>laffon.m@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Muriel LAFFON, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>January 9, 2014</lastchanged_date>
  <firstreceived_date>December 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Facioscapulohumeral</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
